|
CN102186856B
(zh)
|
2008-08-22 |
2014-09-24 |
诺华股份有限公司 |
作为cdk抑制剂的吡咯并嘧啶化合物
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
US20130035336A1
(en)
|
2010-04-13 |
2013-02-07 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
|
|
CN106198656B
(zh)
|
2010-08-18 |
2018-12-11 |
生命科技股份有限公司 |
用于电化学检测装置的微孔的化学涂层
|
|
SG10201508715YA
(en)
*
|
2010-10-25 |
2015-11-27 |
G1 Therapeutics Inc |
Cdk inhibitors
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
AR083797A1
(es)
*
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
CN103402996B
(zh)
*
|
2011-01-04 |
2015-02-11 |
诺瓦提斯公司 |
可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
|
|
AU2014259534B2
(en)
*
|
2011-01-04 |
2016-05-19 |
Novartis Ag |
Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
|
|
AU2012279117A1
(en)
*
|
2011-07-01 |
2014-01-09 |
Novartis Ag |
Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
|
|
RU2014103250A
(ru)
|
2011-07-01 |
2015-08-10 |
Новартис Аг |
Комбинированная терапия
|
|
US9498471B2
(en)
|
2011-10-20 |
2016-11-22 |
The Regents Of The University Of California |
Use of CDK9 inhibitors to reduce cartilage degradation
|
|
US9194840B2
(en)
|
2012-01-19 |
2015-11-24 |
Life Technologies Corporation |
Sensor arrays and methods for making same
|
|
EP2831080B1
(en)
|
2012-03-29 |
2017-03-15 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
WO2014002051A2
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Complement pathway modulators and uses thereof
|
|
EP2867229B1
(en)
|
2012-06-28 |
2017-07-26 |
Novartis AG |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
ES2712190T3
(es)
|
2012-06-28 |
2019-05-09 |
Novartis Ag |
Moduladores de la vía del complemento y sus usos
|
|
WO2014002053A1
(en)
|
2012-06-28 |
2014-01-03 |
Novartis Ag |
Pyrrolidine derivatives and their use as complement pathway modulators
|
|
JP6155332B2
(ja)
|
2012-06-28 |
2017-06-28 |
ノバルティス アーゲー |
ピロリジン誘導体、および補体経路調節因子としてのその使用
|
|
EA201590200A1
(ru)
|
2012-07-12 |
2015-08-31 |
Новартис Аг |
Модуляторы пути активации комплемента и их применение
|
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
HK1213044A1
(zh)
|
2012-08-03 |
2016-06-24 |
Foundation Medicine, Inc. |
人乳头瘤病毒作为肿瘤预後的预测因子
|
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
|
WO2014097125A1
(en)
|
2012-12-20 |
2014-06-26 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
|
EP3327144B1
(en)
|
2013-02-25 |
2020-03-25 |
Novartis AG |
Novel androgen receptor mutation
|
|
CA2901929A1
(en)
|
2013-03-13 |
2014-10-02 |
Abbvie Inc. |
Cdk9 kinase inhibitors
|
|
JP2016516710A
(ja)
|
2013-03-13 |
2016-06-09 |
アッヴィ・インコーポレイテッド |
ピリジン系ｃｄｋ９キナーゼ阻害薬
|
|
TW201446763A
(zh)
|
2013-03-14 |
2014-12-16 |
Abbvie Inc |
吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑
|
|
CN105246890A
(zh)
|
2013-03-14 |
2016-01-13 |
艾伯维公司 |
吡咯并[2,3-b]吡啶cdk9激酶抑制剂
|
|
AU2014244194A1
(en)
*
|
2013-03-14 |
2015-09-10 |
Abbvie Inc. |
Pyrrolopyrimindine CDK9 kinase inhibitors
|
|
EP2967050A4
(en)
*
|
2013-03-15 |
2016-09-28 |
G1 Therapeutics Inc |
HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
|
|
US20140274896A1
(en)
*
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
EP2968291B1
(en)
|
2013-03-15 |
2025-04-16 |
Pharmacosmos Holding A/S |
Hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
EP2976106B1
(en)
|
2013-03-21 |
2021-04-14 |
Array BioPharma Inc. |
Combination therapy comprising a b-raf inhibitor and a second inhibitor
|
|
ES2782003T3
(es)
|
2013-04-16 |
2020-09-09 |
Memorial Sloan Kettering Cancer Center |
Compañero de diagnóstico para inhibidores de CDK4
|
|
ES2900829T3
(es)
|
2013-08-14 |
2022-03-18 |
Novartis Ag |
Terapia combinada para el tratamiento del cáncer
|
|
JP6479812B2
(ja)
*
|
2013-08-28 |
2019-03-06 |
ノバルティス アーゲー |
細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
AR097894A1
(es)
*
|
2013-10-03 |
2016-04-20 |
Hoffmann La Roche |
Inhibidores terapéuticos de cdk8 o uso de los mismos
|
|
WO2015061407A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
|
RU2016125133A
(ru)
|
2013-11-27 |
2018-01-09 |
Новартис Аг |
Комбинированная терапия, включающая применение ингибиторов jak, cdk и pim
|
|
US9476853B2
(en)
|
2013-12-10 |
2016-10-25 |
Life Technologies Corporation |
System and method for forming microwells
|
|
AU2014368927B2
(en)
*
|
2013-12-20 |
2018-10-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
|
AU2014372166B2
(en)
*
|
2013-12-23 |
2017-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
ES2864352T3
(es)
*
|
2013-12-23 |
2021-10-13 |
Novartis Ag |
Combinaciones farmacéuticas
|
|
US9949976B2
(en)
|
2013-12-31 |
2018-04-24 |
Xuanzhu Pharma Co., Ltd. |
Kinase inhibitor and use thereof
|
|
ES2687477T3
(es)
|
2013-12-31 |
2018-10-25 |
Xuanzhu Pharma Co., Ltd. |
Inhibidor de quinasa y su uso
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
EP3660050A1
(en)
|
2014-03-14 |
2020-06-03 |
Novartis AG |
Antibody molecules to lag-3 and uses thereof
|
|
CA2946538A1
(en)
|
2014-04-04 |
2015-10-08 |
Del Mar Pharmaceuticals |
Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
|
|
US20150320754A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9717735B2
(en)
|
2014-04-17 |
2017-08-01 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
AU2015266492B2
(en)
*
|
2014-05-28 |
2017-11-02 |
Fochon Pharmaceuticals, Ltd. |
Certain protein kinase inhibitors
|
|
CN105294737B
(zh)
*
|
2014-07-26 |
2019-02-12 |
广东东阳光药业有限公司 |
Cdk类小分子抑制剂的化合物及其用途
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
CA3000633C
(en)
|
2014-10-14 |
2023-10-03 |
The Regents Of The University Of California |
Use of cdk9 and brd4 inhibitors to inhibit inflammation
|
|
CN114920840A
(zh)
|
2014-10-14 |
2022-08-19 |
诺华股份有限公司 |
针对pd-l1的抗体分子及其用途
|
|
SI3218005T1
(sl)
|
2014-11-12 |
2023-06-30 |
Seagen Inc. |
Z glikanom delujoče spojine, in postopki uporabe
|
|
US10138250B2
(en)
|
2014-12-12 |
2018-11-27 |
Crystal Pharmatech Co., Ltd. |
Salt of pyrrolo[2,3-D]pyrimidine compound and novel polymorph of salt
|
|
CN105111215B
(zh)
*
|
2014-12-12 |
2019-06-18 |
苏州晶云药物科技股份有限公司 |
一种周期蛋白依赖性激酶抑制剂的晶型及其制备方法
|
|
EP3231805B1
(en)
*
|
2014-12-12 |
2020-03-04 |
Crystal Pharmatech Co. Ltd. |
Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
|
|
WO2016126889A1
(en)
*
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|
|
JO3746B1
(ar)
|
2015-03-10 |
2021-01-31 |
Aduro Biotech Inc |
تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
|
|
CN107787226A
(zh)
*
|
2015-03-25 |
2018-03-09 |
诺华股份有限公司 |
药物组合
|
|
FI3283058T3
(fi)
|
2015-04-16 |
2023-03-01 |
Novartis Ag |
Ribosiklibitabletti
|
|
CN106146515B
(zh)
*
|
2015-04-17 |
2020-09-04 |
常州隆赛医药科技有限公司 |
新型激酶抑制剂的制备及应用
|
|
TWI696617B
(zh)
*
|
2015-04-28 |
2020-06-21 |
大陸商上海復尚慧創醫藥研究有限公司 |
特定蛋白質激酶抑制劑
|
|
HRP20211360T1
(hr)
|
2015-05-29 |
2021-11-26 |
Teijin Pharma Limited |
Derivat pirido[3,4-d]pirimidina i njegova farmaceutski prihvatljiva sol
|
|
CN105037236B
(zh)
|
2015-06-04 |
2017-07-28 |
苏州明锐医药科技有限公司 |
瑞博西尼中间体及其制备方法
|
|
CN106336412A
(zh)
*
|
2015-07-10 |
2017-01-18 |
南开大学 |
作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
|
|
CN106699785A
(zh)
*
|
2015-07-13 |
2017-05-24 |
南开大学 |
作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物
|
|
CN105130992B
(zh)
*
|
2015-07-16 |
2018-02-09 |
苏州大学 |
具有激酶抑制活性的含氮杂环化合物、制备方法和用途
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
|
JP2018525425A
(ja)
|
2015-08-28 |
2018-09-06 |
ノバルティス アーゲー |
がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
|
|
EP3340986A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
US20180243304A1
(en)
*
|
2015-08-28 |
2018-08-30 |
Novartis Ag |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
JP2018526377A
(ja)
|
2015-08-28 |
2018-09-13 |
ノバルティス アーゲー |
がんを治療するための、任意にｐｉ３ｋ阻害剤のｂｙｌ７１９を更に含む、ｃｄｋ４／６阻害剤のｌｅｅ０１１とｍｅｋ１／２阻害剤トラメチニブの組み合わせ物
|
|
EP3156406A1
(en)
|
2015-10-14 |
2017-04-19 |
ratiopharm GmbH |
Crystalline forms of ribociclib free base
|
|
RU2018119085A
(ru)
|
2015-11-02 |
2019-12-04 |
Новартис Аг |
Схема введения ингибитора фосфатидилинозитол-3-киназы
|
|
MY198562A
(en)
|
2015-11-03 |
2023-09-05 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
|
CA3002097A1
(en)
|
2015-11-12 |
2017-05-18 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
|
CN106749259B
(zh)
*
|
2015-11-19 |
2019-02-01 |
华东师范大学 |
一种环戊基嘧啶并吡咯类化合物的合成方法
|
|
CN106831780A
(zh)
*
|
2015-12-03 |
2017-06-13 |
南开大学 |
具有cdk4/6和hdac抑制活性的新型杂环衍生物
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
CN105541863B
(zh)
*
|
2016-02-16 |
2017-09-05 |
安纳康科学股份有限公司 |
噻吩[2,3‑c]吡啶衍生物及其作为CDK激酶抑制剂的用途
|
|
US11921116B2
(en)
|
2016-03-09 |
2024-03-05 |
Memorial Sloan Kettering Cancer Center |
Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
|
|
WO2017161253A1
(en)
|
2016-03-18 |
2017-09-21 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
|
US10570141B2
(en)
|
2016-03-25 |
2020-02-25 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
|
|
CN107266451B
(zh)
*
|
2016-04-07 |
2021-12-31 |
上海医药工业研究院 |
瑞布昔利布中间体的制备方法
|
|
JP6921115B2
(ja)
|
2016-04-22 |
2021-08-18 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｃｄｋ４／６の分解および使用法
|
|
WO2017193872A1
(en)
|
2016-05-07 |
2017-11-16 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Certain protein kinase inhibitors
|
|
CN108290899B
(zh)
*
|
2016-06-06 |
2020-09-18 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的吡咯并嘧啶化合物及其应用
|
|
CN114539273A
(zh)
|
2016-06-07 |
2022-05-27 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
CA3028751A1
(en)
*
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based antiproliferative agents
|
|
WO2018005533A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Antiproliferative pyrimidine-based compounds
|
|
WO2018005863A1
(en)
|
2016-07-01 |
2018-01-04 |
G1 Therapeutics, Inc. |
Pyrimidine-based compounds for the treatment of cancer
|
|
AU2017290362B2
(en)
|
2016-07-01 |
2021-08-05 |
Pharmacosmos Holding A/S |
Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
RU2769251C2
(ru)
|
2016-08-23 |
2022-03-29 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Комбинированная терапия для лечения гепатоцеллюлярной карциномы
|
|
WO2018051280A1
(en)
*
|
2016-09-15 |
2018-03-22 |
Dr. Reddy’S Laboratories Limited |
Process for preparation of ribociclib, its acid addition salts
|
|
KR102341660B1
(ko)
|
2016-09-19 |
2021-12-23 |
노파르티스 아게 |
Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
BR112019005526A2
(pt)
|
2016-10-20 |
2019-06-18 |
Pfizer |
agentes antiproliferativos para tratamento de pah
|
|
WO2018081211A1
(en)
*
|
2016-10-26 |
2018-05-03 |
Li George Y |
Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
|
|
WO2018089518A1
(en)
|
2016-11-08 |
2018-05-17 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of modulating anti-tumor immunity
|
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
|
|
WO2018094227A1
(en)
*
|
2016-11-17 |
2018-05-24 |
The University Of North Carolina At Chapel Hill |
Alkyl pyrrolopyrimidine analogs and methods of making and using same
|
|
DK3546458T3
(da)
|
2016-11-28 |
2021-02-22 |
Teijin Pharma Ltd |
((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidin- og ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidinderivater som cdk4/6-inhibitorer til behandling af for eksempel rheumatoid artritis, arteriosklerose, lungefibrose, cerebral infarkt eller kræft
|
|
CA3041854C
(en)
|
2016-11-28 |
2025-05-13 |
Teijin Pharma Limited |
PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
|
|
KR20240023677A
(ko)
|
2016-12-05 |
2024-02-22 |
쥐원 쎄라퓨틱스, 인크. |
화학요법 레지멘 동안의 면역 반응의 보존
|
|
AU2018205262A1
(en)
|
2017-01-06 |
2019-07-11 |
G1 Therapeutics, Inc. |
Combination therapy for the treatment of cancer
|
|
EP3573619A4
(en)
*
|
2017-01-27 |
2020-10-28 |
SignalRX Pharmaceuticals, Inc. |
THIENOPYRANONES AND FURANOPYRANONES AS KINASE, BROMODOMAIN AND CHECKPOINT INHIBITORS
|
|
US11395821B2
(en)
|
2017-01-30 |
2022-07-26 |
G1 Therapeutics, Inc. |
Treatment of EGFR-driven cancer with fewer side effects
|
|
EP3589319A4
(en)
|
2017-03-03 |
2021-07-14 |
Seagen Inc. |
COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
|
|
BR112019019261A2
(pt)
|
2017-03-16 |
2020-06-16 |
Eisai R & D Management Co., Ltd. |
Terapias de combinação para o tratamento de câncer de mama
|
|
HRP20241239T1
(hr)
|
2017-03-23 |
2024-12-06 |
Jacobio Pharmaceuticals Co., Ltd. |
Novi heterociklički derivati korisni kao shp2 inhibitori
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN110494166B
(zh)
|
2017-05-02 |
2022-11-08 |
诺华股份有限公司 |
组合疗法
|
|
CN107118215B
(zh)
*
|
2017-05-06 |
2019-04-05 |
上海耀大生物科技有限公司 |
一种治疗乳腺癌药物瑞博西尼中间体的制备方法
|
|
CN106946880B
(zh)
*
|
2017-05-06 |
2019-04-26 |
南京焕然生物科技有限公司 |
一种制备瑞博西尼中间体的方法
|
|
CN107267481A
(zh)
*
|
2017-05-09 |
2017-10-20 |
上海交通大学医学院附属新华医院 |
Cdk5抗原表位肽及其应用
|
|
CN108929312A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
|
|
CN108929324A
(zh)
*
|
2017-05-22 |
2018-12-04 |
南开大学 |
新型1,1-环丙基二酰胺衍生物的制备与应用
|
|
TW201906818A
(zh)
*
|
2017-05-31 |
2019-02-16 |
美商５１１製藥公司 |
新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用
|
|
WO2018218633A1
(en)
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
MX392531B
(es)
|
2017-06-29 |
2025-03-24 |
G1 Therapeutics Inc |
Formas morficas de g1t38 y metodos de preparacion de las mismas.
|
|
JOP20200015A1
(ar)
|
2017-08-03 |
2022-10-30 |
Novartis Ag |
توليفة علاجية من مثبط كيناز تيروسين egfr من الجيل الثالث ومثبط كيناز يعتمد على سيكلين
|
|
EP4327880A3
(en)
|
2017-08-25 |
2024-05-22 |
Assia Chemical Industries Ltd. |
Solid state form of ribociclib succinate
|
|
EP3676404B1
(en)
|
2017-08-31 |
2025-09-03 |
Novartis AG |
Methods of selecting a treatment for breast cancer patients
|
|
US11286259B2
(en)
|
2017-09-29 |
2022-03-29 |
Hangzhou Solipharma Co., Ltd. |
Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof
|
|
JP7100125B2
(ja)
*
|
2017-10-27 |
2022-07-12 |
フレゼニウス・カビ・オンコロジー・リミテッド |
リボシクリブおよびその塩の改善された調製のためのプロセス
|
|
WO2019097426A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Pharmaceutical combination comprising lsz102 and ribociclib
|
|
RU2020119578A
(ru)
|
2017-11-16 |
2021-12-17 |
Новартис Аг |
Комбинированные терапии
|
|
JP7569688B2
(ja)
|
2017-12-22 |
2024-10-18 |
ハイバーセル，インコーポレイテッド |
ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
|
|
WO2019123364A1
(en)
|
2017-12-22 |
2019-06-27 |
Shilpa Medicare Limited |
Novel polymorphs of ribociclib mono succinate
|
|
WO2019133864A1
(en)
|
2017-12-29 |
2019-07-04 |
Accutar Biotechnology |
DUAL INHIBITORS OF PARP1 and CDK
|
|
CN107936029B
(zh)
*
|
2018-01-08 |
2020-06-30 |
南京奇可药业有限公司 |
一种合成瑞博西尼的方法
|
|
WO2019136451A1
(en)
|
2018-01-08 |
2019-07-11 |
G1 Therapeutics, Inc. |
G1t38 superior dosage regimes
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
TW201940166A
(zh)
*
|
2018-01-29 |
2019-10-16 |
美商貝達醫藥公司 |
作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
|
|
MA51846A
(fr)
|
2018-02-15 |
2021-04-21 |
Nuvation Bio Inc |
Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
|
|
WO2019167068A1
(en)
|
2018-03-01 |
2019-09-06 |
Cipla Limited |
Novel polymorphs of ribociclib succinate
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
CA3043066A1
(en)
|
2018-05-14 |
2019-11-14 |
Apotex Inc. |
Processes for the preparation of ribociclib and intermediates thereof
|
|
WO2019222521A1
(en)
*
|
2018-05-16 |
2019-11-21 |
G1 Therapeutics, Inc. |
Cdk inhibitors for the treatment of neoplastic disorders
|
|
CN108558745A
(zh)
*
|
2018-05-17 |
2018-09-21 |
苏州莱克施德药业有限公司 |
一种帕博西林中间体的合成方法
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019236699A1
(en)
|
2018-06-05 |
2019-12-12 |
Crinetics Pharmaceuticals, Inc. |
Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
AU2019310595B2
(en)
|
2018-07-27 |
2022-11-24 |
1200 Pharma Llc |
CDK inhibitors and uses thereof
|
|
SG11202101397TA
(en)
|
2018-08-13 |
2021-03-30 |
Beijing Percans Oncology Co Ltd |
Biomarkers for cancer therapy
|
|
CN120817904A
(zh)
|
2018-08-24 |
2025-10-21 |
法码科思莫斯有限公司 |
1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
|
|
CA3112496A1
(en)
*
|
2018-09-13 |
2020-03-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Salts of substituted pyrrolopyrimidine cdk inhibitor, crystal and use thereof
|
|
WO2020063760A1
(en)
|
2018-09-26 |
2020-04-02 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
WO2020084389A1
(en)
|
2018-10-23 |
2020-04-30 |
Lupin Limited |
Ribociclib intermediate and process for preparation thereof
|
|
CN117105933A
(zh)
|
2018-10-31 |
2023-11-24 |
吉利德科学公司 |
具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
|
|
CN113227089B
(zh)
|
2018-10-31 |
2024-07-05 |
吉利德科学公司 |
作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
CN109400612A
(zh)
*
|
2018-12-24 |
2019-03-01 |
重庆三圣实业股份有限公司 |
一种瑞博西尼的制备方法及其产品和用途
|
|
EP3902805A4
(en)
|
2018-12-28 |
2023-03-01 |
SPV Therapeutics Inc. |
CYCLINE-DEPENDENT KINASE INHIBITORS
|
|
US20220056037A1
(en)
*
|
2018-12-28 |
2022-02-24 |
Spv Therapeutics Inc. |
Cyclin-dependent kinase inhibitors
|
|
KR20210119444A
(ko)
|
2019-01-23 |
2021-10-05 |
노파르티스 아게 |
7-사이클로펜틸-2-(5-피페라진-1-일-피리딘-2-일아미노)-7h-피롤로[2,3-d]피리미딘-6-카복실산 디메틸아미드의 석신산염의 신규한 결정질 형태
|
|
IL284835B2
(en)
|
2019-02-12 |
2025-08-01 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and ribociclib
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
US20220296595A1
(en)
|
2019-05-05 |
2022-09-22 |
Qilu Regor Therapeutics Inc. |
Cdk inhibitors
|
|
WO2020225827A1
(en)
|
2019-05-08 |
2020-11-12 |
Mylan Laboratories Limited |
Novel polymorphs of ribociclib succinate
|
|
BR112021022335A2
(pt)
|
2019-05-13 |
2021-12-28 |
Novartis Ag |
Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
|
|
UY38700A
(es)
|
2019-05-20 |
2020-12-31 |
Novartis Ag |
Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
ES3044436T3
(en)
*
|
2019-06-04 |
2025-11-26 |
Step Pharma S A S |
N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamide as a human ctps1 inhibitor for the treatment of proliferative diseases
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
CN112094272A
(zh)
|
2019-06-18 |
2020-12-18 |
北京睿熙生物科技有限公司 |
Cdk激酶抑制剂
|
|
KR20220054347A
(ko)
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
WO2021038590A1
(en)
|
2019-08-30 |
2021-03-04 |
Mylan Laboratories Limited |
Novel polymorph of ribociclib succinate
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
JP7657792B2
(ja)
*
|
2019-11-07 |
2025-04-07 |
クリネティックス ファーマシューティカルズ，インク． |
メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用
|
|
IL293940A
(en)
*
|
2019-12-16 |
2022-08-01 |
Lunella Biotech Inc |
Selective cancer drugs cdk4/6 inhibitors
|
|
EP4077325A4
(en)
|
2019-12-16 |
2023-11-15 |
Lunella Biotech, Inc. |
THERAPEUTIC AGENTS SELECTIVE CDK 4/6 INHIBITORS
|
|
EP4077307B1
(en)
|
2019-12-18 |
2025-03-12 |
Crinetics Pharmaceuticals, Inc. |
Gem-disubstituted piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
TW202135859A
(zh)
|
2019-12-20 |
2021-10-01 |
瑞士商諾華公司 |
組合療法
|
|
CN116234803A
(zh)
|
2019-12-23 |
2023-06-06 |
冰洲石生物科技公司 |
用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
|
|
WO2021133563A1
(en)
|
2019-12-23 |
2021-07-01 |
Crinetics Pharmaceuticals, Inc. |
Spirocyclic piperidine melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
|
|
US20230118053A1
(en)
*
|
2020-03-27 |
2023-04-20 |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd. |
Combination of anti-her2 antibody and cdk inhibitior for tumor treatment
|
|
US20240000789A1
(en)
|
2020-05-12 |
2024-01-04 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|
|
EP4140997A4
(en)
*
|
2020-05-12 |
2023-09-06 |
Suzhou Alphama Biotechnology Co., Ltd. |
PYRIDINE ACETAMIDE DERIVATIVE AS CDK INHIBITOR, PREPARATION METHOD AND USE THEREOF
|
|
EP4141004A4
(en)
*
|
2020-05-12 |
2023-08-23 |
Suzhou Alphama Biotechnology Co., Ltd. |
POLYCYCLIC AMIDE DERIVATIVE SERVING AS A CDK9 INHIBITOR, METHOD FOR PREPARING IT AND ITS USE
|
|
ES3048084T3
(en)
|
2020-05-19 |
2025-12-09 |
Pharmacosmos Holding As |
Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
|
|
AU2021287380A1
(en)
*
|
2020-06-11 |
2023-01-05 |
Lunella Biotech, Inc. |
Selective CDK4/6 inhibitor cancer therapeutics
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN112375081B
(zh)
*
|
2020-11-23 |
2022-04-12 |
中国医学科学院医药生物技术研究所 |
具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
|
|
US20240042051A1
(en)
|
2020-11-24 |
2024-02-08 |
Francesca Rocchetti |
Mcl-1 inhibitor antibody-drug conjugates and methods of use
|
|
US11999786B2
(en)
|
2020-11-24 |
2024-06-04 |
Novartis Ag |
Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2022162122A1
(en)
|
2021-01-29 |
2022-08-04 |
Biotx.Ai Gmbh |
Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
|
|
KR20230170644A
(ko)
|
2021-02-02 |
2023-12-19 |
르 라보레또레 쎄르비에르 |
선택적 bcl-xl protac 화합물 및 사용 방법
|
|
CA3211644A1
(en)
|
2021-03-19 |
2022-09-22 |
Christine FERRARA-COOK |
Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease
|
|
EP4313987A2
(en)
|
2021-04-01 |
2024-02-07 |
KRKA, d.d., Novo mesto |
Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024517788A
(ja)
|
2021-05-05 |
2024-04-23 |
ノバルティス アーゲー |
Ｍｐｎｓｔの処置のための化合物及び組成物
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4370126A4
(en)
|
2021-07-16 |
2025-05-28 |
Dana-Farber Cancer Institute, Inc. |
Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
|
|
TW202320795A
(zh)
|
2021-07-26 |
2023-06-01 |
美商凱爾科迪股份有限公司 |
使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
|
|
WO2023008885A1
(ko)
*
|
2021-07-27 |
2023-02-02 |
보로노이바이오 주식회사 |
피롤로피리미딘 유도체 화합물 및 이의 용도
|
|
TWI848533B
(zh)
|
2022-01-25 |
2024-07-11 |
瑞士商諾華公司 |
瑞博西尼藥物組成物
|
|
CN114456180B
(zh)
*
|
2022-02-18 |
2023-07-25 |
贵州大学 |
用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用
|
|
US12275738B2
(en)
|
2022-04-08 |
2025-04-15 |
Biolexis Therapeutics, Inc. |
CDK9 inhibitors
|
|
EP4504709A4
(en)
*
|
2022-04-08 |
2025-12-24 |
Biolexis Therapeutics Inc |
CDK9 inhibitors
|
|
US20250339547A1
(en)
|
2022-05-20 |
2025-11-06 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
WO2023225320A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
EP4580631A1
(en)
|
2022-08-31 |
2025-07-09 |
Arvinas Operations, Inc. |
Dosage regimens of estrogen receptor degraders
|
|
EP4605088A1
(en)
*
|
2022-10-21 |
2025-08-27 |
Novartis AG |
Molecular glue degrader compounds and uses thereof
|
|
JP2025539034A
(ja)
|
2022-11-11 |
2025-12-03 |
アストラゼネカ・アクチエボラーグ |
癌の治療のための併用療法
|
|
WO2024115680A1
(en)
|
2022-12-01 |
2024-06-06 |
Krka, D.D., Novo Mesto |
Ribociclib salts and formulations thereof
|
|
CN120752058A
(zh)
|
2023-03-10 |
2025-10-03 |
诺华股份有限公司 |
panRAS抑制剂抗体-药物缀合物及其使用方法
|
|
WO2024229406A1
(en)
|
2023-05-04 |
2024-11-07 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
CN121057581A
(zh)
|
2023-05-05 |
2025-12-02 |
阿斯利康(瑞典)有限公司 |
用于在治疗乳腺癌中使用的卡帕塞替尼、cdk4/6抑制剂和氟维司群的组合
|
|
WO2024235844A1
(en)
|
2023-05-12 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods of preventing on-target genotoxicity induced by nucleases
|
|
WO2025034702A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Rmc-6291 for use in the treatment of ras protein-related disease or disorder
|
|
CN117069663B
(zh)
*
|
2023-08-31 |
2023-12-26 |
四川维亚本苑生物科技有限公司 |
一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
|
|
WO2025051337A1
(en)
|
2023-09-06 |
2025-03-13 |
Afyx Development A/S |
Compositions and methods for treating and preventing oral cancer
|
|
US20250114357A1
(en)
*
|
2023-10-10 |
2025-04-10 |
Biolexis Therapeutics, Inc. |
Bifunctional protac and molecular glue compounds and methods of use thereof
|
|
TW202530228A
(zh)
|
2023-10-12 |
2025-08-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
WO2025111450A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd74 antibody-drug conjugates and methods of use thereof
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
WO2025219830A1
(en)
|
2024-04-15 |
2025-10-23 |
Novartis Ag |
Pharmaceutical compositions of ribociclib
|
|
WO2025235331A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing pyrazolopyrimidine derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025255438A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
CN120441576B
(zh)
*
|
2025-07-08 |
2025-09-26 |
山东大学 |
一种靶向cdk4/6的化合物及其衍生的放射性示踪剂
|
|
CN120483984B
(zh)
*
|
2025-07-09 |
2025-10-10 |
山东大学 |
一种靶向cdk4/6的分子影像探针标记前体、探针及其制备方法与应用
|